|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01276 HENGRUI PHARMA
Nominal 
75.600 -4.150 (-5.204%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 15,761,194 | 15.885% | 27,984,605 | 22,819,785 | 21,275,271 |
| Cost of Sales | (2,114,962) | 12.900% | (3,848,177) | (3,525,248) | (3,486,639) |
| Gross Profit | 13,646,232 | 16.362% | 24,136,428 | 19,294,537 | 17,788,632 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (41,467) | 20.624% | (21,581) | (72,696) | (62,996) | |
| Profit / (Loss) before Taxation | 5,050,935 | 34.634% | 7,169,690 | 4,667,110 | 3,968,492 | |
| Taxation | (596,264) | 84.335% | (832,695) | (389,289) | (153,351) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (4,564) | -- | (468) | 24,615 | 91,233 | |
| Others | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,450,107 | 29.675% | 6,336,527 | 4,302,436 | 3,906,374 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (242,925) | -33.893% | (597,718) | (471,238) | (378,784) |
| Depreciation & Amortisation | 461,792 | 8.702% | 870,819 | 793,937 | 640,511 |
| Directors' Emoluments | -- | -- | 25,945 | 20,418 | 10,537 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 70.000 | 29.630% | 100.000 | 68.000 | 61.000 |
| DPS (cts) | 0.000 | -- | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.169 | 1.202 | 0.198 |
| NBV per share ($) | 8.820 | -- | -- | -- | -- |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,450,107 |
| %Change | 29.675% |
| EPS / (LPS) | RMB 0.700 |
| NBV Per Share (¥) | RMB 8.820 |